ClinicalTrials.gg
Not yet recruitingNCT03222674Updated Nov 2, 2026

Multi-CAR T Cell Therapy for Acute Myeloid Leukemia

A Phase 1/2 interventional study of Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells in Acute Myeloid Leukemia, sponsored by Shenzhen Geno-Immune Medical Institute. Not yet recruiting at 1 site in China. Open to participants aged 2 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Shenzhen Geno-Immune Medical Institute · Phase 1/2, Interventional, and Treatment

How we know

Updated Nov 2, 2026Study contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
2 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 473 studies in Leukemia, Myeloid, Acute with a site in China — 264 open to participants now, 289 under way, 40 of them phase 3. Leukemia, Myeloid, Acute · China.

Planned enrollment
384th of 433
10 · median 50
Started
2026
with 55 others
Phase 1/2
66 of 473
39 open now
Primary completion
2028-06
later than 239 of 288 live
Registered
52nd of 473
by date

Among the 473 studies in Leukemia, Myeloid, Acute with a site in China, this one is the 384th largest by planned enrollment of the 433 interventional ones that give a count, is one of 56 that started in 2026, is one of 66 in phase 1/2, reaches primary completion later than 239 of the 288 other live ones, and was the 52nd registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

264 of the 473 studies in Leukemia, Myeloid, Acute with a site in China are open now. Recruiting first, the newest first:

259 more — sign in →

All 264 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 2 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 473 studies in Leukemia, Myeloid, Acute with a site in China, or all of them as a file.
02

Study summary

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of multi-CAR T cell therapy targeting different AML surface antigens in patients with relapsed or refractory acute myeloid leukemia (AML). Another goal of the study is to learn more about the function of the multi-CAR T cells and their persistency in the patients.

Read the detailed description

Important Regulatory Notice:

This trial record is only for global academic information registration on ClinicalTrials.gov. Neither the sponsor Beijing Meikang Jimian Biotechnology Co., Ltd. nor collaborator Shenzhen Geno-Immune Medical Institute has obtained NMPA clinical trial approval or clinical technology filing permission to carry out interventional cell therapy trials in mainland China.

ClinicalTrials.gov registration alone does not represent legal approval by Chinese health and drug regulatory authorities.

Acute myeloid leukemia (AML) is a malignant disease characterized by the rapid growth of myeloblasts that build up in the bone marrow and interfere with the production of normal blood cells.

In this study, the patients' own T cells will be genetically modified with lentiviral vectors expressing chimeric antigen receptors. The multi-CAR T cells recognize specific molecules such as CD33, CD38, CD123, CD56, MucI, and CLL1, which are often found expressed on the surface of AML cells. The engineered CAR T cells will be infused into patients.

The purpose of this clinical study is to assess the feasibility, safety and efficacy of the multi-CAR T cell therapy against AML. Another goal of the study is to learn more about the function of the multi-CAR T cells and their persistency in the patients.

03

Conditions studied

  • Acute Myeloid Leukemia

Keywords

  • AML
  • CAR T
  • Muc1,CLL1, CD33, CD38, CD56, and/or CD123
04

Who can participate

Ages eligible
2 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age older than 2 years.
  2. CD33, CD38, CD56, CD123, MucI, and CLL1 expression can be identified in the malignant cells by immuno-histochemical staining or flow cytometry.
  3. performance status (KPS) score is higher than 80 and > 2 months.
  4. Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements: cardiac ≥ 50%, oxygen saturation ≥ 90%, creatinine ≤ 2.5 × , (AST) and alanine aminotransferase (ALT) ≤ 3 × upper limit of normal, total ≤ 2.0mg/dL.
  5. ≥80g/L.
  6. No cell separation .
  7. Abilities to understand and the willingness to provide written .

Exclusion criteria

Exclusion Criteria:

  1. Sever illness or medical condition, which would not permit the patient to be managed according to the protocol, including active uncontrolled infection.
  2. Active bacterial, fungal or viral infection not controlled by adequate treatment.
  3. Known or virus (HBV) infection.
  4. Pregnant or nursing women may not participate.
  5. History of for systemic therapy within the week prior to entering the test.
  6. Previously treatment with any gene therapy products.
  7. Patients, in the opinion of investigators, may not be eligible or not able to comply with the study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Single arm

    CAR T cells to treat AML

    Biological: Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells

Interventions

  • BiologicalMuc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells

    Infusion of Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells

06

What researchers measure

Primary outcomes

  1. percentage of patients with treatment related adverse effect

    percentage of participants with treatment-related adverse events, as assessed by physical exam, vital signs, standard clinical labs and so on.

    Time frame: a year

Secondary outcomes

  1. Anti tumor activity of fourth generation CAR-T cells in patients with relapsed or refractory AML

    scale of CAR copies and leukemic cell burden (for efficacy)

    Time frame: a year

07

Study locations

1 site
08

References and documents

Publications

  • Pei K, Xu H, Wang P, Gan W, Hu Z, Su X, Zhang H, He Y. Anti-CLL1-based CAR T-cells with 4-1-BB or CD28/CD27 stimulatory domains in treating childhood refractory/relapsed acute myeloid leukemia. Cancer Med. 2023 Apr;12(8):9655-9661. doi: 10.1002/cam4.5916. Epub 2023 Apr 9. PubMed 37031462 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jun 2028, 17 months later.

Of 134 non-industry phase 1/2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 110. This study's planned 17 months is below that.

Counting every sponsor, half of 226 studies reached it within 73 months; a quarter within 48 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2017
First posted
Jul 19, 2017
StartEst.
Dec 31, 2026
Primary completionEst.
Jun 30, 2028
CompletionEst.
Dec 31, 2028
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Contact
Study contact's phone or email changed: c•••@szgimi.org→c•••@mkgimi.com. See the current contact
Nov 2, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Shenzhen Geno-immune Medical Institute · Shenzhen, ChinaContact c•••@szgimi.org→c•••@mkgimi.com
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Contact Study contact's phone or email changed: c•••@szgimi.org→c•••@mkgimi.com. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Shenzhen Geno-immune Medical Institute · Shenzhen, ChinaContact c•••@szgimi.org→c•••@mkgimi.com
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03222674
Lead sponsor
Shenzhen Geno-Immune Medical Institute
Responsible party
Lung-Ji Chang (President, Shenzhen Geno-Immune Medical Institute) — Principal investigator
First posted
Jul 19, 2017
Start date
Dec 31, 2026 (estimated)
Primary completion
Jun 30, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 2, 2026

Study contacts

Lung-Ji Chang
Contact
c@mkgimi.com
+86 0755-86573763
Lung-Ji Chang
principal investigator · Shenzhen Geno-Immune Medical Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion